How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy

(2018) Concetta Irace et al.   Cardiovascular Diabetology

SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice

(2018) Dustin M. Lee et al.   Cardiovascular Diabetology

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors

(2018) Sarayut Lahnwong et al.   Cardiovascular Diabetology

Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improves arterial stiffness evaluated by cardio-ankle vascular index in patients with type 2 diabetes

(2018) Nobuhiro Tahara et al.   Current Vascular Pharmacology

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

(2018) Annayya R. Aroor et al.   Cardiovascular Diabetology

Empagliflozin directly improves diastolic function in human heart failure

(2018) Steffen Pabel et al.   EUROPEAN JOURNAL OF HEART FAILURE

Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients

(2018) Laween Uthman et al.   Frontiers in Physiology

Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury

(2017) Pongpan Tanajak et al.   JOURNAL OF ENDOCRINOLOGY

Diabetes: SGLT2 inhibitors and diabetic ketoacidosis — a growing concern

(2017) Guillermo E. Umpierrez   Nature Reviews Endocrinology

Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects

(2017) Ioanna Andreadou et al.   Frontiers in Physiology

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

(2017) Liang Xu et al.   EBioMedicine

Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

(2016) François Briand et al.   DIABETES

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus

(2016) Nikolaus Marx et al.   EUROPEAN HEART JOURNAL

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/−Mice

(2016) Weiling Leng et al.   MEDIATORS OF INFLAMMATION

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

(2015) Michael Roden et al.   Cardiovascular Diabetology

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

(2015) R. Chilton et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis

(2015) A. Ojima et al.   HORMONE AND METABOLIC RESEARCH

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension

(2015) Christian Ott et al.   EuroIntervention

Comparison of an Oscillometric Method with Cardiac Magnetic Resonance for the Analysis of Aortic Pulse Wave Velocity

(2015) Hans-Josef Feistritzer et al.   PLoS One

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

(2014) Matthias Oelze et al.   PLoS One

Oscillometric estimation of aortic pulse wave velocity

(2013) Bernhard Hametner et al.   BLOOD PRESSURE MONITORING

2013 ESH/ESC Guidelines for the management of arterial hypertension

(2013) Giuseppe Mancia et al.   JOURNAL OF HYPERTENSION

Wave Reflections, Assessed With a Novel Method for Pulse Wave Separation, Are Associated With End-Organ Damage and Clinical Outcomes

(2012) Thomas Weber et al.   HYPERTENSION

Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study

(2010) Mary J Roman et al.   JOURNAL OF HYPERTENSION

Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality?

(2009) Kang-Ling Wang et al.   JOURNAL OF HYPERTENSION